Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals

Biotech headlines this week combined significant M&A and regulatory developments with positive clinical readouts: GSK agreed to acquire RAPT Therapeutics for $58.00 per share (~$2.2bn equity value, ~$1.9bn estimated upfront) with closing expected in Q1 2026, and Healthcare Triangle signed to buy Teyame AI CX assets for ~ $50m. Clinical news included Corcept's Phase 3 ROSELLA meeting its overall survival primary endpoint (35% reduction in risk of death; median OS 16.0 vs 11.9 months), Corvus reporting Phase 1 Soquelitinib cohort 4 efficacy (EASI75 75%, EASI90 25%, IGA 0/1 33%), and Nxera's daridorexant Phase 3 meeting primary and secondary endpoints in South Korea. Capital pressures and restructuring were also notable: IO Biotech cut staff and reported $30.7m cash runway only to Q1 2026, while Capricor will resubmit the full HOPE-3 clinical study report for Deramiocel to the FDA in Feb 2026 following a CSR request.

Analysis

Market structure: This week creates clear winners: Corcept (CORT) is a direct beneficiary from a positive OS readout (median OS +4.1 months) which strengthens pricing and formulary negotiating leverage in platinum‑resistant ovarian cancer; GSK/RAPT deal crystallizes ~ $2.2B M&A value and tightens takeover arbitrage spreads. Losers include cash‑strained microcaps (IOBT) with runway to Q1 2026 — likely forced dilutions — and suppliers exposed to downward pricing pressure if payers resist premium cell/combination therapies. Cross‑asset: expect rising equity vol in small biotech, modest widening in high‑yield spreads for single‑asset biotech credits, and limited FX/commodity impact.

Risk assessment: Tail risks include FDA reversal/demand for new trials (Capricor resubmission due Feb 2026) and deal failure/antitrust for RAPT (low probability but high impact to arbitrage). Time horizons: immediate (days) — tender offers and M&A spreads; short (weeks–months) — Feb resubmission, Jan 29 HCTI close and Q1 deal closes; long (quarters–years) — commercialization, payer negotiations, manufacturing scale. Hidden dependencies: manufacturing capacity for allogeneic cell therapies, partner option/territory clauses (NS Pharma for CAPR), and CVRs in LSTA tied to third‑party reversion timelines.

Trade implications: Favor event‑driven long positions in CORT (late‑stage asset, potential buyout candidate) and small, hedged arbitrage in RAPT (buy up to $57.80 if spread <0.4% to $58 offer); short or buy puts on IOBT given runway through Q1 2026 and likely dilution. Use options: buy CORT 6‑month call spread (e.g., 45/60) to limit capital and buy 3‑6 month OTM puts on IOBT (strike ~$0.50) as asymmetric hedge. Rotate 3–5% allocation from microcap discovery biotech into large‑cap pharma/M&A themes (GSK, big caps) to reduce idiosyncratic tail risk.

Contrarian angles: Consensus may overestimate durable pricing for relacorilant — payers could force step edits reducing near‑term revenue; Corvus (CRVS) Phase‑1 enthusiasm may be overbaked given small N (n=24) and typical attrition from Phase 1→3. RAPT arbitrage could be underpriced if GSK pays quickly; conversely, IOBT's selloff may be overdone if they secure bridge financing — consider a small, distressed-recovery spike trade only after confirmation of dilution terms. Historical parallels: cell therapy approvals often see commercial rollouts tempered by capacity and reimbursement, compressing margins in years 1–3.

Key Decisions for Investors

• Establish a 1–2% NAV long position in CORT within 5 trading days; hedge tail risk by buying a 6‑month 45/60 call spread sized to cost no more than 1.5% NAV; plan to trim to 0.5% if post‑presentation uptake or payer commentary is negative within 90 days.
• Initiate an arbitrage long in RAPT (buy shares up to $57.80) sized 0.5–1% NAV if spread to $58 offer is ≤0.4%; set a fail‑rule to exit if regulatory filing/antitrust flags appear or spread widens >1.5% for more than 5 trading days.
• Short IOBT or buy 3‑month puts (strike ~$0.50) equal to a 1% NAV exposure given cash runway to Q1 2026; place stop‑loss at 25% if company announces >$10M non‑dilutive financing or partner deal that extends runway past Q3 2026.
• Buy a speculative 0.5–1% NAV long in CRVS (post‑phase1 signal) with a strict 30% stop; convert to calls (3–6 month) ahead of any Phase 2 readouts or partnership announcements to limit downside.
• Reallocate +3–5% from microcap/early‑discovery biotech into large‑cap pharma (e.g., GSK) or cash‑flowing specialty pharma over the next 2–6 weeks to reduce idiosyncratic liquidity and dilution risk ahead of multiple near‑term binary events (Feb resubmission, Q1 M&A closes).